CTLT - Catalent Inc Stock Price, Fair Value and News

58.66USD+0.21 (+0.36%)Market Closed

Market Summary

USD58.66+0.21

Market Closed

0.36%

CTLT Alerts

1 major insider sales recently.

Big jump in Earnings (Y/Y)

CTLT Stock Price

View Fullscreen

CTLT RSI Chart

CTLT Valuation

Market Cap

10.6B

Price/Earnings (Trailing)

-9.96

Price/Sales (Trailing)

2.57

EV/EBITDA

-15.17

Price/Free Cashflow

-75.83

CTLT Price/Sales (Trailing)

CTLT Profitability

EBT Margin

-30.04%

Return on Equity

-22.32%

Return on Assets

-10.14%

Free Cashflow Yield

-1.32%

CTLT Fundamentals

CTLT Revenue

Revenue (TTM)

4.1B

Rev. Growth (Yr)

3.57%

Rev. Growth (Qtr)

4.88%

CTLT Earnings

Earnings (TTM)

-1.1B

Earnings Growth (Yr)

100%

Earnings Growth (Qtr)

100%

Breaking Down CTLT Revenue

Last 7 days

1.3%

Last 30 days

4.5%

Last 90 days

4.9%

Trailing 12 Months

23.1%

How does CTLT drawdown profile look like?

CTLT Financial Health

Current Ratio

2.66

Debt/Equity

1.03

Debt/Cashflow

0.05

CTLT Investor Care

Shares Dilution (1Y)

0.39%

Diluted EPS (TTM)

-6.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.1B	0	0	0
2023	4.5B	4.3B	4.2B	4.1B
2022	4.7B	4.8B	4.8B	4.7B
2021	5.9B	4.0B	4.2B	4.5B
2020	2.9B	5.2B	5.4B	5.6B
2019	2.5B	2.5B	2.6B	2.7B
2018	2.4B	2.5B	2.5B	2.5B
2017	2.0B	2.1B	2.2B	2.3B
2016	1.8B	1.8B	1.9B	1.9B
2015	1.8B	1.8B	1.8B	1.8B
2014	1.8B	1.8B	1.8B	1.8B
2013	1.8B	1.8B	1.8B	1.8B
2012	0	1.7B	1.7B	1.7B

Get all data in R, Python etc through our Historical Stock Data APIs

About Catalent Inc

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

CEO	Mr. Alessandro Maselli
WEBSITE	catalent.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	17800

Catalent Inc Frequently Asked Questions

What is the ticker symbol for Catalent Inc? What does CTLT stand for in stocks?

CTLT is the stock ticker symbol of Catalent Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Catalent Inc (CTLT)?

As of Fri Jul 26 2024, market cap of Catalent Inc is 10.62 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTLT stock?

You can check CTLT's fair value in chart for subscribers.

Is Catalent Inc a good stock to buy?

The fair value guage provides a quick view whether CTLT is over valued or under valued. Whether Catalent Inc is cheap or expensive depends on the assumptions which impact Catalent Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTLT.

What is Catalent Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, CTLT's PE ratio (Price to Earnings) is -9.96 and Price to Sales (PS) ratio is 2.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTLT PE ratio will change depending on the future growth rate expectations of investors.